{"gene":"DCPS","run_date":"2026-06-09T23:54:41","timeline":{"discoveries":[{"year":2002,"finding":"DcpS was identified as a scavenger mRNA decapping pyrophosphatase that specifically hydrolyzes methylated cap analog (m7GpppN) but not unmethylated cap analog and does not act on intact capped RNA. The central histidine within the HIT motif is critical for decapping activity, defining DcpS as the first HIT-family member with a defined biological function.","method":"Protein purification from mammalian cells, recombinant protein expression, in vitro decapping assays with cap analogs, site-directed mutagenesis of HIT motif histidines","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with mutagenesis, foundational mechanistic study","pmids":["12198172"],"is_preprint":false},{"year":2003,"finding":"DcpS can also function in the 5'-3' mRNA decay pathway by converting m7GDP (the product of Dcp2 decapping) to m7GMP, in addition to its established role in the 3'-5' pathway. This activity was identified in both yeast and human, making m7GMP a general pathway-independent by-product of eukaryotic mRNA decay.","method":"In vitro decapping assays in human cell extracts and yeast, biochemical identification of reaction intermediates and products, fractionation to identify the responsible factor as DcpS","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution replicated in multiple organisms (yeast and human)","pmids":["14523240"],"is_preprint":false},{"year":2005,"finding":"Crystal structures of human DcpS in ligand-free and m7GDP-bound forms revealed that apo-DcpS is a symmetric dimer, while cap-analog-bound DcpS is an asymmetric dimer with one site open and one closed. Tyr273 in the cap-binding pocket undergoes conformational changes upon cap binding and plays an important role in cap binding and product release, as demonstrated by mutagenesis.","method":"X-ray crystallography, site-directed mutagenesis, biochemical decapping assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and biochemical validation in single study","pmids":["15769464"],"is_preprint":false},{"year":2008,"finding":"DcpS is a nucleocytoplasmic shuttling protein containing separable nuclear import and CRM1-dependent export signals. Reduction of DcpS levels via shRNA impaired cap-proximal intron splicing of reporter and endogenous genes. DcpS efficiently displaced the nuclear cap-binding protein Cbp20 from cap structure, and complementation with Cbp20 reversed the splicing defect, indicating DcpS modulates splicing through Cbp20.","method":"shRNA knockdown, immunofluorescence, nuclear import/export signal mapping, in vitro cap-binding displacement assays, reporter splicing assays, rescue by Cbp20 complementation","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (localization, KD phenotype, displacement assay, rescue) in single lab","pmids":["18426921"],"is_preprint":false},{"year":2008,"finding":"DcpS inhibition by C5-substituted quinazolines holds the enzyme in an open, catalytically incompetent conformation. These compounds potently inhibit DcpS decapping activity with potency correlating with SMN2 promoter induction. DcpS was identified as the binding target using protein microarray scanning with a radiolabeled quinazoline probe.","method":"Protein microarray binding with radiolabeled probe, in vitro DcpS decapping activity assays, structural analysis of inhibitor-bound conformation","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical target identification with functional inhibition assay and structural observation, single lab","pmids":["18839960"],"is_preprint":false},{"year":2008,"finding":"Transient state kinetic studies established that DcpS has a dynamic and mutually exclusive cap hydrolysis activity at the two cap binding sites of its dimer. The rate-limiting step and rate of decapping are regulated by cap substrate concentration; decapping is highly efficient at low cap substrate concentrations but regulated (slowed) with excess substrate, reflecting the domain-swapped dimeric architecture.","method":"Transient state kinetic analysis (stopped-flow), mechanistic interpretation based on structural data","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous transient kinetic studies establishing catalytic mechanism, single lab","pmids":["18441014"],"is_preprint":false},{"year":2013,"finding":"The C. elegans DcpS ortholog DCS-1 interacts with the 5'-3' exonuclease XRN-1 to promote microRNA degradation in a manner independent of its decapping scavenger activity, establishing two distinct molecular functions for DCS-1. Loss of dcs-1 increases functional microRNA levels.","method":"Genetic analysis in C. elegans (dcs-1 mutants), protein interaction studies, microRNA level measurements, functional assays separating decapping from XRN-1 cofactor activity","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined molecular phenotype, interaction studies, function separation by multiple approaches","pmids":["23541767"],"is_preprint":false},{"year":2015,"finding":"Human DcpS conserves a role in miRNA turnover, functioning as a nucleocytoplasmic shuttling protein that activates miRNA degradation independently of its scavenger decapping activity in the cytoplasmic compartment. This function requires the 5'-3' exonuclease Xrn2.","method":"DcpS knockdown in human cells, miRNA level measurements, subcellular fractionation, decapping-dead mutant analysis to separate functions, Xrn2 co-dependency assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (KD, mutant, co-dependency) in single lab confirming conserved mechanism","pmids":["26584588"],"is_preprint":false},{"year":2015,"finding":"Loss-of-function mutations in DCPS (splice site and missense variants) abolish decapping activity as shown by in vitro decapping assays with m7G cap derivatives, establishing that DCPS enzymatic activity is required for normal neurological development and cognition in humans.","method":"Patient cells with homozygous DCPS mutations, in vitro decapping assays using m7G cap derivatives as substrates","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic assay on patient-derived material with two independent mutant alleles, replicated in two separate publications (25701870 and 25712129)","pmids":["25701870","25712129"],"is_preprint":false},{"year":2015,"finding":"DcpS, in conjunction with Xrn1, regulates RNA stability in a transcript-selective manner in mammalian cells. Two long non-coding RNAs (DRNT1 and DRNT2) were identified as DcpS-responsive transcripts; DRNT1 stability increased upon DcpS inhibition (RG3039) in a manner dependent on both DcpS catalytic activity and Xrn1.","method":"DcpS inhibitor treatment (RG3039), global mRNA profiling, targeted RNA stability assays, catalytic mutant complementation, Xrn1 knockdown co-dependence","journal":"RNA (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (global screen, stability assay, catalytic mutant, co-dependency), single lab","pmids":["26001796"],"is_preprint":false},{"year":2018,"finding":"DCPS interacts with components of pre-mRNA metabolic pathways including spliceosomes, as revealed by mass spectrometry co-immunoprecipitation in AML cells. DCPS inhibition (RG3039) induces pre-mRNA mis-splicing, contributing to anti-leukemic activity.","method":"Genome-wide CRISPR-Cas9 screen, mass spectrometry after co-immunoprecipitation to identify DCPS interactors, RG3039 treatment with transcriptomic analysis of splicing changes","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-based interactome combined with functional splicing readout upon inhibition, single lab","pmids":["29478914"],"is_preprint":false},{"year":2020,"finding":"DcpS only processes mRNA fragments shorter than three nucleotides. Using NMR (methyl-TROSY) and X-ray crystallography, steric clashes between the enzyme and the third nucleotide of capped mRNA prevent conformational changes required for a catalytically competent active site. Point mutations enlarging the space for the third nucleotide enhance activity on longer substrates. This substrate length-sensing mechanism is conserved from yeast to humans.","method":"Methyl-TROSY NMR spectroscopy, X-ray crystallography, site-directed mutagenesis, in vitro enzymatic assays with substrates of varying length","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure combined with mutagenesis and in vitro activity assays, mechanism conserved across species","pmids":["32723815"],"is_preprint":false},{"year":2022,"finding":"DcpS is required for radial migration, polarity, neurite outgrowth, and identity of developing glutamatergic neurons in the mouse neocortex, as shown by loss-of-function studies. Human neurons derived from DcpS mutation patients showed compromised differentiation and neurite outgrowth.","method":"In utero electroporation knockdown in mouse neocortex, patient-derived human neurons, morphological and marker analysis","journal":"Cerebral cortex (New York, N.Y. : 1991)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotype in two model systems (mouse cortex and patient neurons), single lab","pmids":["34467373"],"is_preprint":false},{"year":2025,"finding":"DcpS loss reduces P-body integrity, and reducing DCPS in human neurons with TDP-43 loss-of-function restores P-body function and RNA turnover, improving neuronal survival. TDP-43 LOF hyperactivates P-bodies, increasing mRNA association and RNA decay, and DCPS acts as a genetic modifier of this pathway.","method":"CRISPRi screening in human neurons, P-body imaging, RNA decay assays, neuronal survival measurements","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPRi screen followed by functional P-body and RNA decay assays, single lab","pmids":["41943580"],"is_preprint":false},{"year":2025,"finding":"DcpS mutant patient-derived cells harbor creatine deficiency and elevated guanidinoacetate (GAA) due to reduced mRNA and protein levels of guanidinoacetate methyltransferase (GAMT). Creatine supplementation reversed compromised neurogenesis and neurite outgrowth during differentiation of DcpS mutant iPSCs into neurons.","method":"Metabolomics of patient-derived cells, iPSC differentiation assays, creatine supplementation rescue experiments, GAMT mRNA/protein quantification","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived cells with metabolomics, iPSC differentiation, and rescue experiments; single lab","pmids":["40410278"],"is_preprint":false},{"year":2014,"finding":"In yeast and human extracts, m7GpppN cap dinucleotides can be degraded through a pathway involving DcpS together with Aph1/FHIT. DcpS acts in concert with NTPs and nucleoside diphosphate kinase for m7GDP elimination, establishing a complete cap catabolism pathway.","method":"In vitro biochemical assays in yeast and human extracts, identification and characterization of Aph1/FHIT as a new scavenger decapping enzyme, pathway reconstitution","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution, single lab, replicated in two organisms","pmids":["25432955"],"is_preprint":false},{"year":2003,"finding":"C. elegans DCS-1 is a member of the Hint branch of the histidine triad superfamily of nucleotide hydrolases with low micromolar specificity for 7-methylguanosine ribonucleotides; trimethylated G substrates are poor competitors. DCS-1 localizes to the nucleus and a perinuclear structure and binds to and directly modulates the activity of the flavin reductase NR1.","method":"Novel fluorescent substrate assay (7meGpppBODIPY), enzyme kinetics, co-immunoprecipitation, immunocytochemistry in COS cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic assay with novel substrate, protein interaction by co-IP, localization by ICC; single lab","pmids":["12871939"],"is_preprint":false},{"year":2022,"finding":"A PROTAC (JCS-1) that recruits VHL E3 ligase to DcpS causes potent, rapid, and sustained DcpS protein degradation at nanomolar concentrations in AML cell lines, validating DcpS as a druggable target whose depletion is anti-proliferative in AML.","method":"PROTAC design, western blot for DcpS degradation, cell viability assays in AML lines","journal":"ACS chemical biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological tool paper demonstrating protein degradation, single lab, limited mechanistic depth about DcpS function per se","pmids":["35749470"],"is_preprint":false}],"current_model":"DCPS (DcpS) is a dimeric HIT-family scavenger pyrophosphatase that hydrolyzes the residual 5' cap structure (m7GpppN or m7GDP) generated during 3'-to-5' mRNA decay by the exosome, producing m7GMP; substrate selectivity is enforced by steric clashes that restrict activity to capped fragments shorter than three nucleotides; DcpS is a nucleocytoplasmic shuttling protein whose displacement of nuclear cap-binding protein Cbp20 from cap structures modulates cap-proximal pre-mRNA splicing, and whose interaction with XRN1/XRN2 promotes miRNA turnover independently of its catalytic activity, while in AML cells it physically associates with spliceosome components and its inhibition causes pre-mRNA mis-splicing; loss of DcpS decapping activity causes creatine deficiency via reduced GAMT expression, which underlies neurogenesis defects, and in the context of TDP-43 proteinopathy, reducing DCPS restores P-body integrity and RNA turnover to improve neuronal survival."},"narrative":{"mechanistic_narrative":"DCPS (DcpS) is a HIT-family scavenger decapping pyrophosphatase that completes eukaryotic mRNA turnover by hydrolyzing the residual cap structure left after exonucleolytic decay [PMID:12198172]. It specifically cleaves the methylated cap (m7GpppN) but not unmethylated cap or intact capped RNA, with a central HIT-motif histidine essential for catalysis [PMID:12198172], and it also converts m7GDP—the product of Dcp2 decapping in the 5'-to-3' pathway—into m7GMP, making cap catabolism a pathway-independent endpoint conserved in yeast and human [PMID:14523240]. Catalysis is governed by a domain-swapped dimer: cap binding produces an asymmetric open/closed dimer in which Tyr273 drives conformational change and product release [PMID:15769464], the two cap sites operate in a dynamic, mutually exclusive manner whose rate is tuned by substrate concentration [PMID:18441014], and steric clashes with the third nucleotide of a capped fragment restrict activity to substrates shorter than three nucleotides, a length-sensing mechanism conserved from yeast to humans [PMID:32723815]. Beyond catalysis, DcpS is a nucleocytoplasmic shuttling protein with separable nuclear import and CRM1-dependent export signals that modulates cap-proximal pre-mRNA splicing by displacing the nuclear cap-binding protein Cbp20 from cap structures [PMID:18426921], and it promotes microRNA and selective transcript turnover by acting with the 5'-to-3' exonucleases XRN1/XRN2 independently of its decapping activity [PMID:23541767, PMID:26584588, PMID:26001796]. In human disease, loss-of-function DCPS mutations abolish decapping activity and cause a neurodevelopmental disorder affecting cognition [PMID:25701870, PMID:25712129]; the resulting neuronal phenotypes—impaired radial migration, neurite outgrowth, and differentiation [PMID:34467373]—are linked to a creatine deficiency arising from reduced GAMT expression that can be reversed by creatine supplementation [PMID:40410278]. DcpS additionally supports P-body integrity, and its reduction restores RNA turnover and neuronal survival in TDP-43 proteinopathy [PMID:41943580]. Its catalytic pocket is pharmacologically tractable: C5-substituted quinazolines trap the enzyme in an inactive open conformation [PMID:18839960].","teleology":[{"year":2002,"claim":"Established the biochemical identity of DcpS as a scavenger decapping enzyme, answering what hydrolyzes the residual cap and defining the first functional HIT-family member.","evidence":"Protein purification, recombinant expression, in vitro decapping assays with cap analogs, and HIT-motif histidine mutagenesis","pmids":["12198172"],"confidence":"High","gaps":["Did not resolve dimeric architecture or catalytic mechanism","In vivo substrate scope not defined"]},{"year":2003,"claim":"Extended DcpS function from the 3'-to-5' pathway to the 5'-to-3' pathway by showing it converts the Dcp2 product m7GDP to m7GMP, making cap catabolism a general decay endpoint.","evidence":"In vitro decapping assays in human and yeast extracts with reaction-intermediate identification and fractionation","pmids":["14523240"],"confidence":"High","gaps":["Did not place the reaction in a complete cap catabolism pathway","Physiological balance between pathways not quantified"]},{"year":2003,"claim":"Characterized the C. elegans ortholog DCS-1 as a Hint-branch nucleotide hydrolase with m7G specificity and an unexpected interaction with flavin reductase NR1, hinting at functions beyond cap hydrolysis.","evidence":"Fluorescent 7meGpppBODIPY substrate kinetics, co-immunoprecipitation, and immunocytochemistry in COS cells","pmids":["12871939"],"confidence":"Medium","gaps":["NR1 interaction not mechanistically connected to decapping","Localization to perinuclear structure not defined"]},{"year":2005,"claim":"Provided the structural basis for cap recognition, showing apo-DcpS is a symmetric dimer that becomes asymmetric on cap binding with Tyr273 driving conformational change.","evidence":"X-ray crystallography of apo and m7GDP-bound DcpS with mutagenesis and decapping assays","pmids":["15769464"],"confidence":"High","gaps":["Did not establish catalytic kinetics of the two-site mechanism","Substrate length discrimination not addressed"]},{"year":2008,"claim":"Defined the catalytic kinetics of the dimer, showing the two cap sites operate in a dynamic, mutually exclusive manner regulated by substrate concentration.","evidence":"Transient-state (stopped-flow) kinetic analysis interpreted against structural data","pmids":["18441014"],"confidence":"High","gaps":["Did not connect kinetics to in vivo decay rates","Regulatory significance of substrate-tuning unclear"]},{"year":2008,"claim":"Revealed a nuclear, decapping-dependent role in splicing, answering whether DcpS has functions beyond cap clearance by linking it to Cbp20 displacement at cap-proximal introns.","evidence":"shRNA knockdown, import/export signal mapping, in vitro cap-binding displacement, reporter splicing assays, and Cbp20 rescue","pmids":["18426921"],"confidence":"High","gaps":["Mechanism of Cbp20 competition in vivo not fully resolved","Genome-wide splicing impact not quantified"]},{"year":2008,"claim":"Identified DcpS as a druggable target of C5-substituted quinazolines that trap it in an inactive open state, linking inhibition to SMN2 induction.","evidence":"Protein microarray binding with radiolabeled probe, in vitro decapping inhibition, and structural conformational analysis","pmids":["18839960"],"confidence":"High","gaps":["Mechanistic link between DcpS inhibition and SMN2 induction not established","Off-target effects of quinazolines not excluded"]},{"year":2013,"claim":"Uncovered a catalytic-independent function in microRNA turnover via direct cooperation with XRN-1, separating two distinct molecular activities of the enzyme.","evidence":"C. elegans dcs-1 genetic analysis, interaction studies, and miRNA level measurements with function-separation assays","pmids":["23541767"],"confidence":"High","gaps":["Mechanism by which DCS-1 stimulates XRN-1 unresolved","Conservation to mammals not shown in this study"]},{"year":2014,"claim":"Reconstituted a complete cap catabolism pathway, placing DcpS alongside Aph1/FHIT and nucleoside diphosphate kinase in m7GDP elimination.","evidence":"In vitro biochemical assays and pathway reconstitution in yeast and human extracts","pmids":["25432955"],"confidence":"Medium","gaps":["In vivo flux through the reconstituted pathway not measured","Relative contributions of DcpS and FHIT unclear"]},{"year":2015,"claim":"Confirmed the conserved catalytic-independent miRNA turnover role in human cells and assigned it to the cytoplasm via Xrn2 dependency.","evidence":"Human DcpS knockdown, miRNA measurements, subcellular fractionation, and decapping-dead mutant analysis","pmids":["26584588"],"confidence":"Medium","gaps":["Direct DcpS-Xrn2 physical interaction not biochemically defined","Single-lab observation"]},{"year":2015,"claim":"Showed transcript-selective RNA stability control by DcpS with XRN1, identifying lncRNAs DRNT1/DRNT2 as responsive transcripts.","evidence":"RG3039 inhibitor treatment, global mRNA profiling, stability assays, catalytic mutant complementation, and Xrn1 knockdown co-dependence","pmids":["26001796"],"confidence":"Medium","gaps":["Basis of transcript selectivity unknown","Direct vs indirect effects on DRNT transcripts not separated"]},{"year":2015,"claim":"Established human disease relevance by showing loss-of-function DCPS mutations abolish decapping activity and are required for normal neurodevelopment and cognition.","evidence":"Patient cells with homozygous DCPS mutations and in vitro decapping assays on m7G cap derivatives (replicated across two publications)","pmids":["25701870","25712129"],"confidence":"High","gaps":["Downstream molecular cause of neurodevelopmental phenotype not defined in this study","Whether catalytic or non-catalytic function drives disease unclear here"]},{"year":2018,"claim":"Linked DcpS to spliceosome physical interactions and pre-mRNA mis-splicing in cancer, providing a basis for its anti-leukemic vulnerability.","evidence":"Genome-wide CRISPR-Cas9 screen, co-IP mass spectrometry interactome, and RG3039 transcriptomic splicing analysis in AML cells","pmids":["29478914"],"confidence":"Medium","gaps":["Which spliceosome interactions are direct not resolved","Causal step from DcpS loss to mis-splicing unclear"]},{"year":2020,"claim":"Defined the substrate length-sensing mechanism, explaining selectivity for fragments shorter than three nucleotides via steric clashes at the active site.","evidence":"Methyl-TROSY NMR, X-ray crystallography, mutagenesis, and in vitro assays with varying-length substrates","pmids":["32723815"],"confidence":"High","gaps":["Physiological consequence of relaxing length specificity not tested","Does not address non-catalytic functions"]},{"year":2022,"claim":"Demonstrated that DcpS loss impairs neuronal migration, polarity, neurite outgrowth, and identity, connecting enzyme function to cortical development.","evidence":"In utero electroporation knockdown in mouse neocortex and patient-derived human neuron morphology/marker analysis","pmids":["34467373"],"confidence":"Medium","gaps":["Molecular mediators of the migration defect not identified","Catalytic vs non-catalytic requirement not dissected"]},{"year":2022,"claim":"Validated DcpS as a degradable drug target by achieving rapid VHL-mediated PROTAC degradation that is anti-proliferative in AML.","evidence":"PROTAC (JCS-1) design with western blot degradation and viability assays in AML lines","pmids":["35749470"],"confidence":"Low","gaps":["Limited mechanistic depth on DcpS biology","Whether anti-proliferative effect reflects catalytic loss or scaffolding loss untested"]},{"year":2025,"claim":"Identified a metabolic mechanism for the neurodevelopmental phenotype: DcpS mutation reduces GAMT expression causing creatine deficiency, reversible by creatine supplementation.","evidence":"Metabolomics of patient-derived cells, iPSC neuronal differentiation, GAMT mRNA/protein quantification, and creatine rescue","pmids":["40410278"],"confidence":"Medium","gaps":["How DcpS loss specifically lowers GAMT mRNA not mechanistically defined","Single-lab finding"]},{"year":2025,"claim":"Positioned DcpS as a modifier of P-body function in TDP-43 proteinopathy, where its reduction restores RNA turnover and neuronal survival.","evidence":"CRISPRi screening in human neurons, P-body imaging, RNA decay assays, and survival measurements","pmids":["41943580"],"confidence":"Medium","gaps":["Molecular basis of DcpS effect on P-body integrity unresolved","Generalizability beyond TDP-43 LOF context untested"]},{"year":null,"claim":"It remains unresolved how DcpS partitions between its catalytic decapping role and its catalytic-independent scaffolding roles (XRN cofactor, splicing, P-body regulation) to produce its developmental and disease phenotypes.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking catalytic vs non-catalytic functions to neurodevelopmental disease","Mechanism connecting cap clearance to GAMT/creatine and P-body regulation unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2,8,11]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,1,11]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,6,7,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,7]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,1,6,7,9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,10]}],"complexes":[],"partners":["XRN1","XRN2","CBP20","FHIT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96C86","full_name":"m7GpppX diphosphatase","aliases":["DCS-1","Decapping scavenger enzyme","Hint-related 7meGMP-directed hydrolase","Histidine triad nucleotide-binding protein 5","Histidine triad protein member 5","HINT-5","Scavenger mRNA-decapping enzyme DcpS"],"length_aa":337,"mass_kda":38.6,"function":"Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-methylguanosine monophosphate (m7GMP). Cleaves cap analog structures like tri-methyl guanosine nucleoside triphosphate (m3(2,2,7)GpppG) with very poor efficiency. Does not hydrolyze unmethylated cap analog (GpppG) and shows no decapping activity on intact m7GpppG-capped mRNA molecules longer than 25 nucleotides. Does not hydrolyze 7-methylguanosine diphosphate (m7GDP) to m7GMP (PubMed:22985415). May also play a role in the 5'->3 mRNA decay pathway; m7GDP, the downstream product released by the 5'->3' mRNA mediated decapping activity, may be also converted by DCPS to m7GMP (PubMed:14523240). Binds to m7GpppG and strongly to m7GDP. Plays a role in first intron splicing of pre-mRNAs. Inhibits activation-induced cell death","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q96C86/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DCPS","classification":"Not Classified","n_dependent_lines":264,"n_total_lines":1208,"dependency_fraction":0.2185430463576159},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DCPS","total_profiled":1310},"omim":[{"mim_id":"616460","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL RECESSIVE 50; MRT50","url":"https://www.omim.org/entry/616460"},{"mim_id":"616459","title":"AL-RAQAD SYNDROME; ARS","url":"https://www.omim.org/entry/616459"},{"mim_id":"610534","title":"DECAPPING ENZYME, SCAVENGER; DCPS","url":"https://www.omim.org/entry/610534"},{"mim_id":"609842","title":"ENHANCER OF mRNA DECAPPING 3; EDC3","url":"https://www.omim.org/entry/609842"},{"mim_id":"606073","title":"NADPH-DEPENDENT DIFLAVIN OXIDOREDUCTASE 1; NDOR1","url":"https://www.omim.org/entry/606073"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":79.5}],"url":"https://www.proteinatlas.org/search/DCPS"},"hgnc":{"alias_symbol":["HSPC015","HINT-5","HSL1","HINT5","DCS-1","DCS1"],"prev_symbol":[]},"alphafold":{"accession":"Q96C86","domains":[{"cath_id":"3.30.200.40","chopping":"47-87_126-138","consensus_level":"medium","plddt":91.9491,"start":47,"end":138},{"cath_id":"3.30.428.10","chopping":"146-335","consensus_level":"medium","plddt":96.1451,"start":146,"end":335}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96C86","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96C86-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96C86-F1-predicted_aligned_error_v6.png","plddt_mean":88.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DCPS","jax_strain_url":"https://www.jax.org/strain/search?query=DCPS"},"sequence":{"accession":"Q96C86","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96C86.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96C86/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96C86"}},"corpus_meta":[{"pmid":"12198172","id":"PMC_12198172","title":"The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12198172","citation_count":218,"is_preprint":false},{"pmid":"1398072","id":"PMC_1398072","title":"Multiple domains of the RNA polymerase I activator hUBF interact with the TATA-binding protein complex hSL1 to mediate transcription.","date":"1992","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1398072","citation_count":153,"is_preprint":false},{"pmid":"16688223","id":"PMC_16688223","title":"Phosphorylation of Hsl1 by Hog1 leads to a G2 arrest essential for cell survival at high osmolarity.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16688223","citation_count":117,"is_preprint":false},{"pmid":"18430890","id":"PMC_18430890","title":"Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS.","date":"2008","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18430890","citation_count":111,"is_preprint":false},{"pmid":"18839960","id":"PMC_18839960","title":"DcpS as a therapeutic target for spinal muscular atrophy.","date":"2008","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/18839960","citation_count":101,"is_preprint":false},{"pmid":"29478914","id":"PMC_29478914","title":"Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29478914","citation_count":101,"is_preprint":false},{"pmid":"14769857","id":"PMC_14769857","title":"In Candida albicans, the Nim1 kinases Gin4 and Hsl1 negatively regulate pseudohypha formation and Gin4 also controls septin organization.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14769857","citation_count":86,"is_preprint":false},{"pmid":"14523240","id":"PMC_14523240","title":"DcpS can act in the 5'-3' mRNA decay pathway in addition to the 3'-5' pathway.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14523240","citation_count":72,"is_preprint":false},{"pmid":"23736298","id":"PMC_23736298","title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23736298","citation_count":72,"is_preprint":false},{"pmid":"11230131","id":"PMC_11230131","title":"GSK-3 kinase Mck1 and calcineurin coordinately mediate Hsl1 down-regulation by Ca2+ in budding yeast.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11230131","citation_count":68,"is_preprint":false},{"pmid":"16207815","id":"PMC_16207815","title":"Caenorhabditis elegans decapping proteins: localization and functional analysis of Dcp1, Dcp2, and DcpS during embryogenesis.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16207815","citation_count":57,"is_preprint":false},{"pmid":"23727836","id":"PMC_23727836","title":"The DcpS inhibitor RG3039 improves motor function in SMA mice.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23727836","citation_count":54,"is_preprint":false},{"pmid":"15383679","id":"PMC_15383679","title":"Nematode m7GpppG and m3(2,2,7)GpppG decapping: activities in Ascaris embryos and characterization of C. elegans scavenger DcpS.","date":"2004","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15383679","citation_count":48,"is_preprint":false},{"pmid":"23541767","id":"PMC_23541767","title":"The decapping scavenger enzyme DCS-1 controls microRNA levels in Caenorhabditis elegans.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23541767","citation_count":47,"is_preprint":false},{"pmid":"15769464","id":"PMC_15769464","title":"Crystal structures of human DcpS in ligand-free and m7GDP-bound forms suggest a dynamic mechanism for scavenger mRNA decapping.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15769464","citation_count":44,"is_preprint":false},{"pmid":"35169143","id":"PMC_35169143","title":"HSL1 and BAM1/2 impact epidermal cell development by sensing distinct signaling peptides.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35169143","citation_count":43,"is_preprint":false},{"pmid":"16431118","id":"PMC_16431118","title":"Enzymatically stable 5' mRNA cap analogs: synthesis and binding studies with human DcpS decapping enzyme.","date":"2006","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16431118","citation_count":43,"is_preprint":false},{"pmid":"25701870","id":"PMC_25701870","title":"Mutations in DCPS and EDC3 in autosomal recessive intellectual disability indicate a crucial role for mRNA decapping in neurodevelopment.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25701870","citation_count":42,"is_preprint":false},{"pmid":"25432955","id":"PMC_25432955","title":"Elimination of cap structures generated by mRNA decay involves the new scavenger mRNA decapping enzyme Aph1/FHIT together with DcpS.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25432955","citation_count":41,"is_preprint":false},{"pmid":"18426921","id":"PMC_18426921","title":"DcpS scavenger decapping enzyme can modulate pre-mRNA splicing.","date":"2008","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18426921","citation_count":36,"is_preprint":false},{"pmid":"24742626","id":"PMC_24742626","title":"Decapping Scavenger (DcpS) enzyme: advances in its structure, activity and roles in the cap-dependent mRNA metabolism.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24742626","citation_count":34,"is_preprint":false},{"pmid":"18948758","id":"PMC_18948758","title":"DcpS, a general modulator of cap-binding protein-dependent processes?","date":"2008","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/18948758","citation_count":34,"is_preprint":false},{"pmid":"12871939","id":"PMC_12871939","title":"Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and Hint-related 7meGMP-directed hydrolase, DCS-1.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12871939","citation_count":33,"is_preprint":false},{"pmid":"25712129","id":"PMC_25712129","title":"Loss of the scavenger mRNA decapping enzyme DCPS causes syndromic intellectual disability with neuromuscular defects.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25712129","citation_count":30,"is_preprint":false},{"pmid":"17900276","id":"PMC_17900276","title":"DCS-1, DCS-2, and DFV share amino acid substitutions at the extracellular RhD protein vestibule.","date":"2007","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/17900276","citation_count":23,"is_preprint":false},{"pmid":"18441014","id":"PMC_18441014","title":"Mechanistic and kinetic analysis of the DcpS scavenger decapping enzyme.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18441014","citation_count":21,"is_preprint":false},{"pmid":"19713762","id":"PMC_19713762","title":"APC/CCdh1 specific degradation of Hsl1 and Clb2 is required for proper stress responses of S. cerevisiae.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19713762","citation_count":21,"is_preprint":false},{"pmid":"31197197","id":"PMC_31197197","title":"The yeast scavenger decapping enzyme DcpS and its application for in vitro RNA recapping.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31197197","citation_count":20,"is_preprint":false},{"pmid":"26001796","id":"PMC_26001796","title":"DcpS is a transcript-specific modulator of RNA in mammalian cells.","date":"2015","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26001796","citation_count":20,"is_preprint":false},{"pmid":"26584588","id":"PMC_26584588","title":"The human decapping scavenger enzyme DcpS modulates microRNA turnover.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26584588","citation_count":19,"is_preprint":false},{"pmid":"18725266","id":"PMC_18725266","title":"Proteomic approach to the identification of novel delta-lactoferrin target genes: Characterization of DcpS, an mRNA scavenger decapping enzyme.","date":"2008","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/18725266","citation_count":19,"is_preprint":false},{"pmid":"27193302","id":"PMC_27193302","title":"Coordinate action of distinct sequence elements localizes checkpoint kinase Hsl1 to the septin collar at the bud neck in Saccharomyces cerevisiae.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/27193302","citation_count":17,"is_preprint":false},{"pmid":"28257199","id":"PMC_28257199","title":"Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA).","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28257199","citation_count":15,"is_preprint":false},{"pmid":"32723815","id":"PMC_32723815","title":"Molecular basis of the selective processing of short mRNA substrates by the DcpS mRNA decapping enzyme.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32723815","citation_count":14,"is_preprint":false},{"pmid":"37245534","id":"PMC_37245534","title":"Ferroptosis induced by DCPS depletion diminishes hepatic metastasis in uveal melanoma.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37245534","citation_count":13,"is_preprint":false},{"pmid":"28945765","id":"PMC_28945765","title":"In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28945765","citation_count":13,"is_preprint":false},{"pmid":"20546305","id":"PMC_20546305","title":"Structural requirements for Caenorhabditis elegans DcpS substrates based on fluorescence and HPLC enzyme kinetic studies.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20546305","citation_count":13,"is_preprint":false},{"pmid":"35749470","id":"PMC_35749470","title":"Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC.","date":"2022","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35749470","citation_count":12,"is_preprint":false},{"pmid":"33375958","id":"PMC_33375958","title":"Objective assessment of chronic pain in donkeys using the donkey chronic pain scale (DCPS): A scale-construction study.","date":"2020","source":"Veterinary journal (London, England : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/33375958","citation_count":11,"is_preprint":false},{"pmid":"26055638","id":"PMC_26055638","title":"The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.","date":"2015","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/26055638","citation_count":11,"is_preprint":false},{"pmid":"30289615","id":"PMC_30289615","title":"An additional patient with a homozygous mutation in DCPS contributes to the delination of Al-Raqad syndrome.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30289615","citation_count":9,"is_preprint":false},{"pmid":"25959423","id":"PMC_25959423","title":"A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS.","date":"2015","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/25959423","citation_count":8,"is_preprint":false},{"pmid":"39009344","id":"PMC_39009344","title":"Protein kinase Hsl1 phosphorylates Pah1 to inhibit phosphatidate phosphatase activity and regulate lipid synthesis in Saccharomyces cerevisiae.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39009344","citation_count":7,"is_preprint":false},{"pmid":"34467373","id":"PMC_34467373","title":"mRNA-Decapping Associated DcpS Enzyme Controls Critical Steps of Neuronal Development.","date":"2022","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/34467373","citation_count":6,"is_preprint":false},{"pmid":"26049109","id":"PMC_26049109","title":"Effect of different N7 substitution of dinucleotide cap analogs on the hydrolytic susceptibility towards scavenger decapping enzymes (DcpS).","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26049109","citation_count":5,"is_preprint":false},{"pmid":"16140270","id":"PMC_16140270","title":"Role of a novel dual flavin reductase (NR1) and an associated histidine triad protein (DCS-1) in menadione-induced cytotoxicity.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16140270","citation_count":5,"is_preprint":false},{"pmid":"39350123","id":"PMC_39350123","title":"Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39350123","citation_count":4,"is_preprint":false},{"pmid":"32770650","id":"PMC_32770650","title":"Leukoencephalopathy in Al-Raqad syndrome: Expanding the clinical and neuroimaging features caused by a biallelic novel missense variant in DCPS.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/32770650","citation_count":4,"is_preprint":false},{"pmid":"40661462","id":"PMC_40661462","title":"DCPS modulates TDP-43 mediated neurodegeneration through P-body regulation.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40661462","citation_count":2,"is_preprint":false},{"pmid":"40410278","id":"PMC_40410278","title":"Creatine mitigates neurogenesis impairment caused by defective DcpS decapping.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40410278","citation_count":1,"is_preprint":false},{"pmid":"30858142","id":"PMC_30858142","title":"The natural antisense transcript NATTD regulates the transcription of decapping scavenger (DcpS) enzyme.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30858142","citation_count":1,"is_preprint":false},{"pmid":"40344930","id":"PMC_40344930","title":"The first case of Al-Raqad syndrome in Japan is associated with a homozygous DCPS exonic variant resulting in aberrant splicing.","date":"2025","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/40344930","citation_count":1,"is_preprint":false},{"pmid":"18066754","id":"PMC_18066754","title":"Kinetics of C. elegans DcpS cap hydrolysis studied by fluorescence spectroscopy.","date":"2007","source":"Nucleosides, nucleotides & nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/18066754","citation_count":1,"is_preprint":false},{"pmid":"41943580","id":"PMC_41943580","title":"DCPS modulates TDP-43-linked neurodegeneration through P-body-mediated RNA decay.","date":"2026","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/41943580","citation_count":0,"is_preprint":false},{"pmid":"41888450","id":"PMC_41888450","title":"Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome.","date":"2026","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41888450","citation_count":0,"is_preprint":false},{"pmid":"42204260","id":"PMC_42204260","title":"Liquid-liquid phase separation and the formation of amyloid fibrils from DcpS scavenger enzymes.","date":"2026","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/42204260","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.24.678264","title":"Liquid-Liquid Phase Separation-mediated formation of amyloid fibrils from DcpS scavenger enzymes","date":"2025-09-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.24.678264","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.07.634209","title":"Nim1-related kinases regulate septin organization and cytokinesis by modulating Hof1 at the cell division site","date":"2025-02-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.07.634209","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.18.629192","title":"Defective DcpS Decapping Manifests in Creatine Deficiency Syndrome and Neurological impairment","date":"2024-12-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.18.629192","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27911,"output_tokens":4449,"usd":0.075234,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12479,"output_tokens":5163,"usd":0.095735,"stage2_stop_reason":"end_turn"},"total_usd":0.170969,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"DcpS was identified as a scavenger mRNA decapping pyrophosphatase that specifically hydrolyzes methylated cap analog (m7GpppN) but not unmethylated cap analog and does not act on intact capped RNA. The central histidine within the HIT motif is critical for decapping activity, defining DcpS as the first HIT-family member with a defined biological function.\",\n      \"method\": \"Protein purification from mammalian cells, recombinant protein expression, in vitro decapping assays with cap analogs, site-directed mutagenesis of HIT motif histidines\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with mutagenesis, foundational mechanistic study\",\n      \"pmids\": [\"12198172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DcpS can also function in the 5'-3' mRNA decay pathway by converting m7GDP (the product of Dcp2 decapping) to m7GMP, in addition to its established role in the 3'-5' pathway. This activity was identified in both yeast and human, making m7GMP a general pathway-independent by-product of eukaryotic mRNA decay.\",\n      \"method\": \"In vitro decapping assays in human cell extracts and yeast, biochemical identification of reaction intermediates and products, fractionation to identify the responsible factor as DcpS\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution replicated in multiple organisms (yeast and human)\",\n      \"pmids\": [\"14523240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structures of human DcpS in ligand-free and m7GDP-bound forms revealed that apo-DcpS is a symmetric dimer, while cap-analog-bound DcpS is an asymmetric dimer with one site open and one closed. Tyr273 in the cap-binding pocket undergoes conformational changes upon cap binding and plays an important role in cap binding and product release, as demonstrated by mutagenesis.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, biochemical decapping assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and biochemical validation in single study\",\n      \"pmids\": [\"15769464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DcpS is a nucleocytoplasmic shuttling protein containing separable nuclear import and CRM1-dependent export signals. Reduction of DcpS levels via shRNA impaired cap-proximal intron splicing of reporter and endogenous genes. DcpS efficiently displaced the nuclear cap-binding protein Cbp20 from cap structure, and complementation with Cbp20 reversed the splicing defect, indicating DcpS modulates splicing through Cbp20.\",\n      \"method\": \"shRNA knockdown, immunofluorescence, nuclear import/export signal mapping, in vitro cap-binding displacement assays, reporter splicing assays, rescue by Cbp20 complementation\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (localization, KD phenotype, displacement assay, rescue) in single lab\",\n      \"pmids\": [\"18426921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DcpS inhibition by C5-substituted quinazolines holds the enzyme in an open, catalytically incompetent conformation. These compounds potently inhibit DcpS decapping activity with potency correlating with SMN2 promoter induction. DcpS was identified as the binding target using protein microarray scanning with a radiolabeled quinazoline probe.\",\n      \"method\": \"Protein microarray binding with radiolabeled probe, in vitro DcpS decapping activity assays, structural analysis of inhibitor-bound conformation\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical target identification with functional inhibition assay and structural observation, single lab\",\n      \"pmids\": [\"18839960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Transient state kinetic studies established that DcpS has a dynamic and mutually exclusive cap hydrolysis activity at the two cap binding sites of its dimer. The rate-limiting step and rate of decapping are regulated by cap substrate concentration; decapping is highly efficient at low cap substrate concentrations but regulated (slowed) with excess substrate, reflecting the domain-swapped dimeric architecture.\",\n      \"method\": \"Transient state kinetic analysis (stopped-flow), mechanistic interpretation based on structural data\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous transient kinetic studies establishing catalytic mechanism, single lab\",\n      \"pmids\": [\"18441014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The C. elegans DcpS ortholog DCS-1 interacts with the 5'-3' exonuclease XRN-1 to promote microRNA degradation in a manner independent of its decapping scavenger activity, establishing two distinct molecular functions for DCS-1. Loss of dcs-1 increases functional microRNA levels.\",\n      \"method\": \"Genetic analysis in C. elegans (dcs-1 mutants), protein interaction studies, microRNA level measurements, functional assays separating decapping from XRN-1 cofactor activity\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined molecular phenotype, interaction studies, function separation by multiple approaches\",\n      \"pmids\": [\"23541767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Human DcpS conserves a role in miRNA turnover, functioning as a nucleocytoplasmic shuttling protein that activates miRNA degradation independently of its scavenger decapping activity in the cytoplasmic compartment. This function requires the 5'-3' exonuclease Xrn2.\",\n      \"method\": \"DcpS knockdown in human cells, miRNA level measurements, subcellular fractionation, decapping-dead mutant analysis to separate functions, Xrn2 co-dependency assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (KD, mutant, co-dependency) in single lab confirming conserved mechanism\",\n      \"pmids\": [\"26584588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss-of-function mutations in DCPS (splice site and missense variants) abolish decapping activity as shown by in vitro decapping assays with m7G cap derivatives, establishing that DCPS enzymatic activity is required for normal neurological development and cognition in humans.\",\n      \"method\": \"Patient cells with homozygous DCPS mutations, in vitro decapping assays using m7G cap derivatives as substrates\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic assay on patient-derived material with two independent mutant alleles, replicated in two separate publications (25701870 and 25712129)\",\n      \"pmids\": [\"25701870\", \"25712129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DcpS, in conjunction with Xrn1, regulates RNA stability in a transcript-selective manner in mammalian cells. Two long non-coding RNAs (DRNT1 and DRNT2) were identified as DcpS-responsive transcripts; DRNT1 stability increased upon DcpS inhibition (RG3039) in a manner dependent on both DcpS catalytic activity and Xrn1.\",\n      \"method\": \"DcpS inhibitor treatment (RG3039), global mRNA profiling, targeted RNA stability assays, catalytic mutant complementation, Xrn1 knockdown co-dependence\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (global screen, stability assay, catalytic mutant, co-dependency), single lab\",\n      \"pmids\": [\"26001796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DCPS interacts with components of pre-mRNA metabolic pathways including spliceosomes, as revealed by mass spectrometry co-immunoprecipitation in AML cells. DCPS inhibition (RG3039) induces pre-mRNA mis-splicing, contributing to anti-leukemic activity.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen, mass spectrometry after co-immunoprecipitation to identify DCPS interactors, RG3039 treatment with transcriptomic analysis of splicing changes\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-based interactome combined with functional splicing readout upon inhibition, single lab\",\n      \"pmids\": [\"29478914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DcpS only processes mRNA fragments shorter than three nucleotides. Using NMR (methyl-TROSY) and X-ray crystallography, steric clashes between the enzyme and the third nucleotide of capped mRNA prevent conformational changes required for a catalytically competent active site. Point mutations enlarging the space for the third nucleotide enhance activity on longer substrates. This substrate length-sensing mechanism is conserved from yeast to humans.\",\n      \"method\": \"Methyl-TROSY NMR spectroscopy, X-ray crystallography, site-directed mutagenesis, in vitro enzymatic assays with substrates of varying length\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure combined with mutagenesis and in vitro activity assays, mechanism conserved across species\",\n      \"pmids\": [\"32723815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DcpS is required for radial migration, polarity, neurite outgrowth, and identity of developing glutamatergic neurons in the mouse neocortex, as shown by loss-of-function studies. Human neurons derived from DcpS mutation patients showed compromised differentiation and neurite outgrowth.\",\n      \"method\": \"In utero electroporation knockdown in mouse neocortex, patient-derived human neurons, morphological and marker analysis\",\n      \"journal\": \"Cerebral cortex (New York, N.Y. : 1991)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotype in two model systems (mouse cortex and patient neurons), single lab\",\n      \"pmids\": [\"34467373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DcpS loss reduces P-body integrity, and reducing DCPS in human neurons with TDP-43 loss-of-function restores P-body function and RNA turnover, improving neuronal survival. TDP-43 LOF hyperactivates P-bodies, increasing mRNA association and RNA decay, and DCPS acts as a genetic modifier of this pathway.\",\n      \"method\": \"CRISPRi screening in human neurons, P-body imaging, RNA decay assays, neuronal survival measurements\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPRi screen followed by functional P-body and RNA decay assays, single lab\",\n      \"pmids\": [\"41943580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DcpS mutant patient-derived cells harbor creatine deficiency and elevated guanidinoacetate (GAA) due to reduced mRNA and protein levels of guanidinoacetate methyltransferase (GAMT). Creatine supplementation reversed compromised neurogenesis and neurite outgrowth during differentiation of DcpS mutant iPSCs into neurons.\",\n      \"method\": \"Metabolomics of patient-derived cells, iPSC differentiation assays, creatine supplementation rescue experiments, GAMT mRNA/protein quantification\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived cells with metabolomics, iPSC differentiation, and rescue experiments; single lab\",\n      \"pmids\": [\"40410278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In yeast and human extracts, m7GpppN cap dinucleotides can be degraded through a pathway involving DcpS together with Aph1/FHIT. DcpS acts in concert with NTPs and nucleoside diphosphate kinase for m7GDP elimination, establishing a complete cap catabolism pathway.\",\n      \"method\": \"In vitro biochemical assays in yeast and human extracts, identification and characterization of Aph1/FHIT as a new scavenger decapping enzyme, pathway reconstitution\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution, single lab, replicated in two organisms\",\n      \"pmids\": [\"25432955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C. elegans DCS-1 is a member of the Hint branch of the histidine triad superfamily of nucleotide hydrolases with low micromolar specificity for 7-methylguanosine ribonucleotides; trimethylated G substrates are poor competitors. DCS-1 localizes to the nucleus and a perinuclear structure and binds to and directly modulates the activity of the flavin reductase NR1.\",\n      \"method\": \"Novel fluorescent substrate assay (7meGpppBODIPY), enzyme kinetics, co-immunoprecipitation, immunocytochemistry in COS cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic assay with novel substrate, protein interaction by co-IP, localization by ICC; single lab\",\n      \"pmids\": [\"12871939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A PROTAC (JCS-1) that recruits VHL E3 ligase to DcpS causes potent, rapid, and sustained DcpS protein degradation at nanomolar concentrations in AML cell lines, validating DcpS as a druggable target whose depletion is anti-proliferative in AML.\",\n      \"method\": \"PROTAC design, western blot for DcpS degradation, cell viability assays in AML lines\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological tool paper demonstrating protein degradation, single lab, limited mechanistic depth about DcpS function per se\",\n      \"pmids\": [\"35749470\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DCPS (DcpS) is a dimeric HIT-family scavenger pyrophosphatase that hydrolyzes the residual 5' cap structure (m7GpppN or m7GDP) generated during 3'-to-5' mRNA decay by the exosome, producing m7GMP; substrate selectivity is enforced by steric clashes that restrict activity to capped fragments shorter than three nucleotides; DcpS is a nucleocytoplasmic shuttling protein whose displacement of nuclear cap-binding protein Cbp20 from cap structures modulates cap-proximal pre-mRNA splicing, and whose interaction with XRN1/XRN2 promotes miRNA turnover independently of its catalytic activity, while in AML cells it physically associates with spliceosome components and its inhibition causes pre-mRNA mis-splicing; loss of DcpS decapping activity causes creatine deficiency via reduced GAMT expression, which underlies neurogenesis defects, and in the context of TDP-43 proteinopathy, reducing DCPS restores P-body integrity and RNA turnover to improve neuronal survival.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DCPS (DcpS) is a HIT-family scavenger decapping pyrophosphatase that completes eukaryotic mRNA turnover by hydrolyzing the residual cap structure left after exonucleolytic decay [#0]. It specifically cleaves the methylated cap (m7GpppN) but not unmethylated cap or intact capped RNA, with a central HIT-motif histidine essential for catalysis [#0], and it also converts m7GDP—the product of Dcp2 decapping in the 5'-to-3' pathway—into m7GMP, making cap catabolism a pathway-independent endpoint conserved in yeast and human [#1]. Catalysis is governed by a domain-swapped dimer: cap binding produces an asymmetric open/closed dimer in which Tyr273 drives conformational change and product release [#2], the two cap sites operate in a dynamic, mutually exclusive manner whose rate is tuned by substrate concentration [#5], and steric clashes with the third nucleotide of a capped fragment restrict activity to substrates shorter than three nucleotides, a length-sensing mechanism conserved from yeast to humans [#11]. Beyond catalysis, DcpS is a nucleocytoplasmic shuttling protein with separable nuclear import and CRM1-dependent export signals that modulates cap-proximal pre-mRNA splicing by displacing the nuclear cap-binding protein Cbp20 from cap structures [#3], and it promotes microRNA and selective transcript turnover by acting with the 5'-to-3' exonucleases XRN1/XRN2 independently of its decapping activity [#6, #7, #9]. In human disease, loss-of-function DCPS mutations abolish decapping activity and cause a neurodevelopmental disorder affecting cognition [#8]; the resulting neuronal phenotypes—impaired radial migration, neurite outgrowth, and differentiation [#12]—are linked to a creatine deficiency arising from reduced GAMT expression that can be reversed by creatine supplementation [#14]. DcpS additionally supports P-body integrity, and its reduction restores RNA turnover and neuronal survival in TDP-43 proteinopathy [#13]. Its catalytic pocket is pharmacologically tractable: C5-substituted quinazolines trap the enzyme in an inactive open conformation [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the biochemical identity of DcpS as a scavenger decapping enzyme, answering what hydrolyzes the residual cap and defining the first functional HIT-family member.\",\n      \"evidence\": \"Protein purification, recombinant expression, in vitro decapping assays with cap analogs, and HIT-motif histidine mutagenesis\",\n      \"pmids\": [\"12198172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve dimeric architecture or catalytic mechanism\", \"In vivo substrate scope not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended DcpS function from the 3'-to-5' pathway to the 5'-to-3' pathway by showing it converts the Dcp2 product m7GDP to m7GMP, making cap catabolism a general decay endpoint.\",\n      \"evidence\": \"In vitro decapping assays in human and yeast extracts with reaction-intermediate identification and fractionation\",\n      \"pmids\": [\"14523240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not place the reaction in a complete cap catabolism pathway\", \"Physiological balance between pathways not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Characterized the C. elegans ortholog DCS-1 as a Hint-branch nucleotide hydrolase with m7G specificity and an unexpected interaction with flavin reductase NR1, hinting at functions beyond cap hydrolysis.\",\n      \"evidence\": \"Fluorescent 7meGpppBODIPY substrate kinetics, co-immunoprecipitation, and immunocytochemistry in COS cells\",\n      \"pmids\": [\"12871939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NR1 interaction not mechanistically connected to decapping\", \"Localization to perinuclear structure not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided the structural basis for cap recognition, showing apo-DcpS is a symmetric dimer that becomes asymmetric on cap binding with Tyr273 driving conformational change.\",\n      \"evidence\": \"X-ray crystallography of apo and m7GDP-bound DcpS with mutagenesis and decapping assays\",\n      \"pmids\": [\"15769464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish catalytic kinetics of the two-site mechanism\", \"Substrate length discrimination not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the catalytic kinetics of the dimer, showing the two cap sites operate in a dynamic, mutually exclusive manner regulated by substrate concentration.\",\n      \"evidence\": \"Transient-state (stopped-flow) kinetic analysis interpreted against structural data\",\n      \"pmids\": [\"18441014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect kinetics to in vivo decay rates\", \"Regulatory significance of substrate-tuning unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a nuclear, decapping-dependent role in splicing, answering whether DcpS has functions beyond cap clearance by linking it to Cbp20 displacement at cap-proximal introns.\",\n      \"evidence\": \"shRNA knockdown, import/export signal mapping, in vitro cap-binding displacement, reporter splicing assays, and Cbp20 rescue\",\n      \"pmids\": [\"18426921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Cbp20 competition in vivo not fully resolved\", \"Genome-wide splicing impact not quantified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified DcpS as a druggable target of C5-substituted quinazolines that trap it in an inactive open state, linking inhibition to SMN2 induction.\",\n      \"evidence\": \"Protein microarray binding with radiolabeled probe, in vitro decapping inhibition, and structural conformational analysis\",\n      \"pmids\": [\"18839960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between DcpS inhibition and SMN2 induction not established\", \"Off-target effects of quinazolines not excluded\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Uncovered a catalytic-independent function in microRNA turnover via direct cooperation with XRN-1, separating two distinct molecular activities of the enzyme.\",\n      \"evidence\": \"C. elegans dcs-1 genetic analysis, interaction studies, and miRNA level measurements with function-separation assays\",\n      \"pmids\": [\"23541767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which DCS-1 stimulates XRN-1 unresolved\", \"Conservation to mammals not shown in this study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reconstituted a complete cap catabolism pathway, placing DcpS alongside Aph1/FHIT and nucleoside diphosphate kinase in m7GDP elimination.\",\n      \"evidence\": \"In vitro biochemical assays and pathway reconstitution in yeast and human extracts\",\n      \"pmids\": [\"25432955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo flux through the reconstituted pathway not measured\", \"Relative contributions of DcpS and FHIT unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirmed the conserved catalytic-independent miRNA turnover role in human cells and assigned it to the cytoplasm via Xrn2 dependency.\",\n      \"evidence\": \"Human DcpS knockdown, miRNA measurements, subcellular fractionation, and decapping-dead mutant analysis\",\n      \"pmids\": [\"26584588\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DcpS-Xrn2 physical interaction not biochemically defined\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed transcript-selective RNA stability control by DcpS with XRN1, identifying lncRNAs DRNT1/DRNT2 as responsive transcripts.\",\n      \"evidence\": \"RG3039 inhibitor treatment, global mRNA profiling, stability assays, catalytic mutant complementation, and Xrn1 knockdown co-dependence\",\n      \"pmids\": [\"26001796\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of transcript selectivity unknown\", \"Direct vs indirect effects on DRNT transcripts not separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established human disease relevance by showing loss-of-function DCPS mutations abolish decapping activity and are required for normal neurodevelopment and cognition.\",\n      \"evidence\": \"Patient cells with homozygous DCPS mutations and in vitro decapping assays on m7G cap derivatives (replicated across two publications)\",\n      \"pmids\": [\"25701870\", \"25712129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream molecular cause of neurodevelopmental phenotype not defined in this study\", \"Whether catalytic or non-catalytic function drives disease unclear here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked DcpS to spliceosome physical interactions and pre-mRNA mis-splicing in cancer, providing a basis for its anti-leukemic vulnerability.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 screen, co-IP mass spectrometry interactome, and RG3039 transcriptomic splicing analysis in AML cells\",\n      \"pmids\": [\"29478914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which spliceosome interactions are direct not resolved\", \"Causal step from DcpS loss to mis-splicing unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the substrate length-sensing mechanism, explaining selectivity for fragments shorter than three nucleotides via steric clashes at the active site.\",\n      \"evidence\": \"Methyl-TROSY NMR, X-ray crystallography, mutagenesis, and in vitro assays with varying-length substrates\",\n      \"pmids\": [\"32723815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of relaxing length specificity not tested\", \"Does not address non-catalytic functions\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated that DcpS loss impairs neuronal migration, polarity, neurite outgrowth, and identity, connecting enzyme function to cortical development.\",\n      \"evidence\": \"In utero electroporation knockdown in mouse neocortex and patient-derived human neuron morphology/marker analysis\",\n      \"pmids\": [\"34467373\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediators of the migration defect not identified\", \"Catalytic vs non-catalytic requirement not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Validated DcpS as a degradable drug target by achieving rapid VHL-mediated PROTAC degradation that is anti-proliferative in AML.\",\n      \"evidence\": \"PROTAC (JCS-1) design with western blot degradation and viability assays in AML lines\",\n      \"pmids\": [\"35749470\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Limited mechanistic depth on DcpS biology\", \"Whether anti-proliferative effect reflects catalytic loss or scaffolding loss untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified a metabolic mechanism for the neurodevelopmental phenotype: DcpS mutation reduces GAMT expression causing creatine deficiency, reversible by creatine supplementation.\",\n      \"evidence\": \"Metabolomics of patient-derived cells, iPSC neuronal differentiation, GAMT mRNA/protein quantification, and creatine rescue\",\n      \"pmids\": [\"40410278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How DcpS loss specifically lowers GAMT mRNA not mechanistically defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Positioned DcpS as a modifier of P-body function in TDP-43 proteinopathy, where its reduction restores RNA turnover and neuronal survival.\",\n      \"evidence\": \"CRISPRi screening in human neurons, P-body imaging, RNA decay assays, and survival measurements\",\n      \"pmids\": [\"41943580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of DcpS effect on P-body integrity unresolved\", \"Generalizability beyond TDP-43 LOF context untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how DcpS partitions between its catalytic decapping role and its catalytic-independent scaffolding roles (XRN cofactor, splicing, P-body regulation) to produce its developmental and disease phenotypes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking catalytic vs non-catalytic functions to neurodevelopmental disease\", \"Mechanism connecting cap clearance to GAMT/creatine and P-body regulation unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 8, 11]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 6, 7, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 1, 6, 7, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"XRN1\", \"XRN2\", \"Cbp20\", \"FHIT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}